BPC-157 vs Ipamorelin: Tissue Repair vs Growth Hormone
Here is how these two compounds compare — based on published research, not marketing claims.
BPC-157
212
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
Ipamorelin
48
Indexed Studies
Human Trials
Evidence Level
Yes
Human Trials
Not Approved
FDA Status
PSI OVERVIEW
Here is the key difference between these compounds and what it means for the research.
BPC-157 and ipamorelin are frequently mentioned together in peptide therapy discussions but target completely different systems. BPC-157 is a tissue repair peptide. Ipamorelin is a growth hormone secretagogue. One fixes damage. The other optimizes a hormone. Understanding this distinction prevents misuse.
Key Differences
| Attribute | BPC-157 | Ipamorelin |
|---|---|---|
| Evidence Level | Human Trials | Human Trials |
| Category | Body Protection Compound | GH Secretagogue |
| Human Data | Over 200 animal studies, two human pilot studies. PSI rates L3. | Multiple human pharmacodynamic studies. PSI rates L3. |
| Safety Profile | Extensive animal safety data. Two human pilot studies. Not FDA-approved. | Minimal off-target effects. Does not raise cortisol or prolactin. Generally well-tolerated. |
| Key Limitations | Most research from one group. Human data is early. | Not FDA-approved. Less clinical outcome data than sermorelin. |
Mechanism Comparison
HOW THEY WORK
These compounds work through different biological pathways. Here is how each one operates at the cellular level.
BPC-157
Promotes angiogenesis, growth factor expression, and nitric oxide regulation at injury sites. Directly targets the tissue repair cascade.
Ipamorelin
Selectively activates ghrelin receptors to stimulate pituitary GH release without raising cortisol or prolactin. The most selective GH secretagogue available.
BPC-157 works locally at injury sites. Ipamorelin works systemically through the pituitary gland. BPC-157 sends repair signals to damaged tissue. Ipamorelin tells your brain to make more growth hormone. They operate in different biological systems entirely.
Research Evidence
RESEARCH EVIDENCE
Between these compounds, researchers have published over 260 indexed studies. Here are the key findings.
Both L3. BPC-157 has more total publications. Ipamorelin has cleaner pharmacological data. For tissue repair, BPC-157 is the researched option. For GH optimization, ipamorelin is the researched option.
For a specific injury — BPC-157 targets the repair process directly.
For systemic GH optimization — ipamorelin is the appropriate tool.
For recovery protocols — some practitioners use both, targeting different aspects of recovery.
Do not use ipamorelin expecting tissue repair, or BPC-157 expecting GH elevation.
Key Limitations
- •No head-to-head comparison.
- •They are not pharmacological alternatives to each other.
- •Combination use is common but unstudied.
- •Both lack Phase III trials.
PSI Verdict
SUPPORTED BY EVIDENCE
BPC-157 promotes tissue repair through angiogenesis and growth factor pathways. Ipamorelin selectively stimulates GH release without off-target hormone effects. Both are effective within their respective domains.
NOT YET ESTABLISHED
Neither replaces the other. Combining them has not been studied in controlled settings. Whether GH elevation from ipamorelin enhances tissue repair beyond what BPC-157 provides alone is unknown.
CONFIDENCE LEVEL
High for the distinction: these serve different purposes. The comparison is useful for protocol planning, not for choosing one over the other for the same goal.
Community Discussion
WHAT THE COMMUNITY IS SAYING
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
BPC-157
"BPC-157 healed my gut issues in two weeks"Plausible but unproven in humans
"BPC-157 fixed my tendon injury faster than anything"Plausible but unproven in humans
"BPC-157 is completely safe with no side effects"Insufficient evidence
Ipamorelin
"Ipamorelin is the cleanest GH secretagogue with the fewest side effects"Plausible but unproven
"Combined with CJC-1295 it mimics natural GH pulsing"Plausible but unproven
"It helped with my joint pain and recovery"Anecdotal only
Safety Comparison
SAFETY PROFILE
What is currently known about the safety of each compound based on available research.
BPC-157
Extensive animal safety data. Two human pilot studies. Not FDA-approved.
Ipamorelin
Minimal off-target effects. Does not raise cortisol or prolactin. Generally well-tolerated.
Both have favorable safety profiles within their research contexts. Ipamorelin's selectivity is a notable advantage. BPC-157 has more total safety data from its larger study count.
WHAT THE RESEARCH SUGGESTS
Different tools. Different toolboxes. BPC-157 for tissue repair. Ipamorelin for GH. Comparing them is only useful if you are deciding which system to target.
Frequently Asked Questions
Explore Each Compound
For the full evidence profile, PSI Verdict, and indexed research data, visit each compound's dedicated page.
Looking for a physician experienced with peptide therapy?
Every physician in the PSI directory is individually verified for active licensure, board certification, and clinical peptide experience.
Browse the PSI Physician Directory →Explore Individual Research Pages
Related PSI Resources
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.